ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 174 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $98 | -100.0% | 100 | -98.7% | 0.00% | -100.0% |
| Q4 2019 | $470,000 | +62.6% | 7,876 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $289,000 | -23.3% | 7,876 | -2.9% | 0.00% | 0.0% |
| Q2 2019 | $377,000 | -66.0% | 8,111 | -70.6% | 0.00% | -75.0% |
| Q1 2019 | $1,108,000 | +206.9% | 27,604 | +251.7% | 0.00% | +300.0% |
| Q4 2018 | $361,000 | +7.4% | 7,849 | +3.8% | 0.00% | 0.0% |
| Q3 2018 | $336,000 | +60.8% | 7,562 | +42.0% | 0.00% | 0.0% |
| Q2 2018 | $209,000 | -81.3% | 5,326 | -65.5% | 0.00% | -80.0% |
| Q1 2018 | $1,116,000 | +255.4% | 15,436 | +223.2% | 0.01% | +400.0% |
| Q4 2017 | $314,000 | +119.6% | 4,776 | +54.1% | 0.00% | 0.0% |
| Q2 2017 | $143,000 | +31.2% | 3,100 | -6.1% | 0.00% | 0.0% |
| Q1 2017 | $109,000 | – | 3,301 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |